BOT Share Price Performance
AU$0.15
-0.19 (-56.52%)
Price AU$0.15
Share PriceAU$0.15
BOT Community Narratives
There are no narratives available yet.
Recent BOT News & Updates
No updates
Botanix Pharmaceuticals Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.02
- Gross Margin
- -87.64%
- Net Profit Margin
- -1,898.88%
- Debt/Equity Ratio
- 0%
Botanix Pharmaceuticals Limited Competitors
About BOT
- Founded
- 1984
- Employees
- n/a
- CEO
- WebsiteView website
Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia and the United States. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. Botanix Pharmaceuticals Limited was incorporated in 1984 and is based in West Perth, Australia.
Australian Market Performance
- 7 Days: 0.7%
- 3 Months: 7.6%
- 1 Year: 14.0%
- Year to Date: 6.4%
Over the last 7 days, the market has remained flat, although notably the Consumer Discretionary sector gained 3.1% in that time. More promisingly, the market is up 14% over the past year. As for the next few years, earnings are expected to grow by 11% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading